成都先导(688222.SH)：拟增资参股公司先衍生物2400万元

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The ultra-long-acting antihypertensive drug LDR2402 targeting the AGT site has entered Phase II clinical trials, with the first subject already dosed [1] - The clinical trial application (IND) for the small nucleic acid new drug LDR2515 injection (targeting INHBE) for obesity treatment has recently received implied approval from the China National Medical Products Administration (CDE) [1] Group 2: Financing and Shareholding - XianYuan is a subsidiary and affiliated party of Chengdu XianDao, with a registered capital of 17.24 million yuan [1] - Chengdu XianDao plans to subscribe to an additional registered capital of 24 million yuan at a pre-investment valuation of 450 million yuan, increasing its shareholding in XianYuan from 23.20% [1] - The lead investor in this financing round is Chengdu Angel DaoYuan GuoSheng Medical Health Venture Capital Partnership (Limited Partnership), with other investors including affiliated parties Cao Jiaming and Huabo Medical [1]